Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections

2016/05/12 by Michael P. Veve, Jamie L. Wagner, Rachel M. Kenney +2 · 19 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Antibiotic Resistance in Bacteria #Urinary Tract Infections Management #Antibiotics Pharmacokinetics and Efficacy

paper · doi:10.1016/j.ijantimicag.2016.04.014

Cited by

• Retrospective multicenter evaluation of oral step-down versus intravenous carbapenem treatment of extended-spectrum beta-lactamase-producing Escherichia coli urinary tract infections
• Unplanned Healthcare Encounters in Drug-Resistant Urinary Tract Infections in Emergency Departments
• High rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of ESBL producers from Nepal. [europepmc]
• Fosfomycin Susceptibility in Multidrug-Resistant Enterobacteriaceae Species and Vancomycin-Resistant Enterococci Urinary Isolates. [europepmc]
• Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. [europepmc]
• Impact of an antimicrobial stewardship program on urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. [europepmc]
• Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST). [europepmc]
• Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. [europepmc]
• The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. [europepmc]
• ESBL-producing Escherichia coli and Its Rapid Rise among Healthy People. [europepmc]
• Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections. [europepmc]
• Treatment duration of complicated urinary tract infections by extended-spectrum beta-lactamases producing enterobacterales. [europepmc]
• Interplay among Different Fosfomycin Resistance Mechanisms in Klebsiella pneumoniae. [europepmc]
• Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. [europepmc]
• Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial. [europepmc]
• The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections. [europepmc]
• Challenges to Early Discharge of Patients with Upper Urinary Tract Infections by ESBL Producers: TMP/SMX as a Step-Down Therapy for Shorter Hospitalization and Lower Costs. [europepmc]
• Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales. [europepmc]
• [UhpT E350Q mutation along with the presence of fosA6/5 genes in the genome probably contributes to inherent fosfomycin resistance of Klebsiella pneumoniae ]. [europepmc]